- Research works
- 61 ▲ 162% vs 2013–17
- Citations
- 892 14.6 per fractional work
- Top-10% rate
- 25.5% record average 16.5%
- Open access
- 53% world 28%
Not ranked overall: MedSIR (Spain) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does MedSIR (Spain) specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.7× the share of its output that it takes of world research.
- MedicineField · 21.3 works3.7×
- Health SciencesDomain · 21.5 works3.1×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.7×. Every wedge is a field page.
- Medicine 3.7×
- Biochemistry, Genetics and Molecular Biology 2.7×
- Economics, Econometrics and Finance 2.4×
- Immunology and Microbiology 1.1×
- Chemistry 0.5×
- Mathematics 0.3×
- Health Professions 0.3×
- Materials Science 0.2×
- Psychology 0.2×
- Decision Sciences 0.2×
- Engineering 0.2×
- Physics and Astronomy 0.1×
- Business, Management and Accounting 0.1×
- Environmental Science 0.1×
- Social Sciences 0.0×
- Computer Science 0.0×
Who are the top researchers at MedSIR (Spain)?
Ranked on the composite score, José Manuel Pérez-García, Miguel Sampayo-Cordero and María Gión lead among researchers whose main affiliation is MedSIR (Spain).
- 1 José Manuel Pérez-García Spain · #450,661 worldwide 71 citations · 26 works
- 2 Miguel Sampayo-Cordero Spain · #709,918 worldwide 23 citations · 15 works
- 3 María Gión Spain · #1,355,760 worldwide 11 citations · 22 works
Which keywords describe research at MedSIR (Spain)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Quality of Life, Metastatic Breast Cancer, Clinical Practice Guidelines, Radiotherapy, Survival Analysis and Metastatic.
- Cognitive Function
- Prevention
- Patient-Reported Outcomes
- Cost of Care
- Depression
- Anxiety
- Biomarkers
- Cancer
- Chemotherapy-Induced Peripheral Neuropathy
- Clinical Trials
- Prognostic Markers
- Neoadjuvant Therapy
- Immunotherapy
- Breast Tumours
- HER2
- EGFR
- Metastatic
- Radiotherapy
- Metastatic Breast Cancer
- Breast Cancer
- Chemotherapy
- Quality of Life
- Clinical Practice Guidelines
- Survival Analysis
- Trastuzumab
- Gene Expression
- Metastasis
- CDK4/6 Inhibitors
- Molecular Subtypes
- Palbociclib
- Treatment Response
- Targeted Therapy
- Taxanes
- Cancer Therapy
- Metabolic Syndrome
- Cancer Survivorship
- Survival
- Financial Toxicity
- Physical Activity
- Tumor Microenvironment
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy6▲ 30×15 topics
- Breast Cancer6▲ 82×9 topics
- Quality of Life4▲ 9.5×7 topics
- Metastatic Breast Cancer4▲ 218×2 topics
- Clinical Practice Guidelines4▲ 22×7 topics
- Radiotherapy3▲ 29×7 topics
- Survival Analysis3▲ 34×4 topics
- Metastatic2▲ 118×2 topics
- Trastuzumab2▲ 160×2 topics
- EGFR2▲ 249×1 topic
- Gene Expression2▲ 12×4 topics
- HER22▲ 249×1 topic
- Metastasis2▲ 21×5 topics
- Breast Tumours2▲ 141×1 topic
- CDK4/6 Inhibitors2▲ 271×1 topic
- Immunotherapy2▲ 9.4×9 topics
- Molecular Subtypes2▲ 82×3 topics
- Neoadjuvant Therapy2▲ 29×3 topics
- Palbociclib2▲ 271×1 topic
- Prognostic Markers2▲ 64×2 topics
- Treatment Response2▲ 141×1 topic
- Clinical Trials2▲ 9.3×6 topics
- Targeted Therapy2▲ 28×4 topics
- Chemotherapy-Induced Peripheral Neuropathy2▲ 177×1 topic
- Taxanes2▲ 177×1 topic
- Cancer2▲ 4.0×15 topics
- Cancer Therapy2▲ 9.6×7 topics
- Biomarkers2▲ 7.5×5 topics
- Metabolic Syndrome2▲ 6.2×6 topics
- Anxiety1▲ 8.3×2 topics
- Cancer Survivorship1▲ 54×2 topics
- Depression1▲ 4.5×2 topics
- Survival1▲ 29×3 topics
- Cost of Care1▲ 125×1 topic
- Financial Toxicity1▲ 125×1 topic
- Patient-Reported Outcomes1▲ 71×1 topic
- Physical Activity1▲ 7.7×1 topic
- Prevention1▲ 8.7×3 topics
- Tumor Microenvironment1▲ 8.1×4 topics
- Cognitive Function1▲ 19×2 topics
Which research topics does MedSIR (Spain) publish most on?
By volume in 2022–2025: HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies and Cancer Treatment and Pharmacology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 HER2/EGFR in Cancer Research Oncology 2 works
- 2 Breast Cancer Treatment Studies Cancer Research 2 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 4 Cancer Treatment and Pharmacology Oncology 2 works
- 5 Cancer survivorship and care Oncology 1 works
- 6 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
- 7 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 8 Brain Metastases and Treatment Pulmonary and Respiratory Medicine 1 works
- 9 Lung Cancer Research Studies Oncology 1 works
- 10 Oral health in cancer treatment Pulmonary and Respiratory Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has MedSIR (Spain)'s research output changed?
Output in 2018–2022 was 162% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Barcelona
- Universitat de Barcelona
- Universitat Politècnica de Catalunya
- Universitat Pompeu Fabra
- Hospital Clínic de Barcelona
- Vall d'Hebron Hospital Universitari
- Hospital de Sant Pau
- Universitat Oberta de Catalunya
- Institució Catalana de Recerca i Estudis Avançats
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.